{"id":"W3032096744","doi":"10.1200/jco.2020.38.15_suppl.9001","title":"KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System; University of Toronto","funders":"","keywords":"Medicine; Placebo; Carboplatin; Internal medicine; Population; Etoposide; Interim analysis; Pembrolizumab; Clinical endpoint; Oncology; Clinical trial; Cisplatin; Chemotherapy; Cancer; Pathology; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.002013305,0.00034957,0.002534447,0.0001273864,0.0001760433,0.00003157368,0.000322066,0.0004798964,0.0005191393],"category_scores_gemma":[0.01012316,0.0002237337,0.0005669993,0.0002107348,0.0004079728,0.0001370766,0.0002113205,0.001684022,0.00001058231],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004490904,"about_ca_system_score_gemma":0.005405172,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001218601,"about_ca_topic_score_gemma":0.0003394967,"domain_scores_codex":[0.9955638,0.0003710637,0.002323893,0.0005090287,0.0006125796,0.0006196362],"domain_scores_gemma":[0.987959,0.008020091,0.001569911,0.0002555331,0.001180105,0.001015414],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"not_applicable","study_design_scores_codex":[0.6868974,0.002295306,0.0444676,0.00263979,0.005063762,0.006024451,0.004973514,0.001072586,0.003061134,0.000181947,0.1304716,0.1128509],"study_design_scores_gemma":[0.2068043,0.0905166,0.03359648,0.0007501755,0.001580336,0.000587406,0.001106603,0.01193077,0.002109756,0.0002301885,0.6501088,0.0006786493],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8786619,0.01183799,0.0009703418,0.1034581,0.001142252,0.002116637,0.00005457945,0.00004087274,0.001717291],"genre_scores_gemma":[0.8927283,0.05645387,0.006258408,0.03236153,0.006588603,0.0001651034,0.000007761635,0.0001216978,0.005314699],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5196372,"threshold_uncertainty_score":0.998215,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2029837320610601,"score_gpt":0.5117943962480638,"score_spread":0.3088106641870036,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}